Comparative Pharmacology
Head-to-head clinical analysis: APRETUDE versus DESCOVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRETUDE versus DESCOVY.
APRETUDE vs DESCOVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor (INSTI) that inhibits the integration of HIV-1 DNA into host genomic DNA, which is essential for viral replication. It binds to the active site of integrase and blocks the strand transfer step of retroviral DNA integration.
DESCOVY is a fixed-dose combination of emtricitabine and tenofovir alafenamide. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine-5'-triphosphate and incorporating into viral DNA, causing chain termination. Tenofovir alafenamide is a prodrug of tenofovir, which is also an NRTI; it is taken up by cells and converted to tenofovir diphosphate, which inhibits HIV-1 reverse transcriptase via chain termination after incorporation into viral DNA.
600 mg IM every 2 months, initiated as two consecutive monthly loading doses of 600 mg each, for HIV-1 pre-exposure prophylaxis.
One tablet (emtricitabine 200 mg / tenofovir alafenamide 25 mg) orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 40 hours following subcutaneous injection, supporting monthly dosing.
TAF: 0.51 hours (intracellular tenofovir diphosphate ~150 hours). FTC: 10 hours (intracellular triphosphate >39 hours). Clinical context: Long intracellular half-life supports once-daily dosing.
Renal (approximately 30% as unchanged drug) and fecal (approximately 50% as metabolites and unchanged drug) following oral administration.
Tenofovir alafenamide (TAF): 80% excreted renally as unchanged drug via glomerular filtration and active tubular secretion; 15% recovered in feces. Emtricitabine (FTC): 70% excreted renally as unchanged drug via glomerular filtration and active tubular secretion; 14% as metabolites; remainder in feces.
Category C
Category C
Antiretroviral
Antiretroviral